Portal vein thrombosis or Budd-Chiari syndrome
Conditions
Interventions
dabigatran
Sponsors
Chiba University Graduate School of Medicine, Department of Gastroenterology and Nephrology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients with portal vein thrombosis or Budd-Chiari syndrome diagnosed by radiological findings 2) patients who is scheduled for, or receiving anticoagulant therapy for portal vein thrombosis or Budd-Chiari syndrome
Exclusion criteria
Exclusion criteria: 1) patients with Child-Pugh classification C 2) patients with severe cardiac or pulmonary dysfunction 3) patients with hemoglobin A1c > 6.5 4) patients with treatment history of dabigatran 5) patients who need treatment of dabigatran combined with other anticoagulant or antiplatelet agent 6) patients with creatinine clearance < 50 ml/min 7) patients who have bleeding symptom or hemophliac 8) patients with peptic ulcers 9) patients with history of cerebral bleeding within 6 months 10) patients with epidural catheter 11) patients with use of non-steroidal anti-inflammatory drugs 12) patients with use of P-glycoprotein repressor 13) patients with use of itoraconazole 14) patients using cardiac pacemaker 15) pregnant woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic effect of dabigatran on portal vein thrombosis or Budd-Chiari syndrome | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Safety of dabigatran for portal vein thrombosis or Budd-Chiari syndrome 2) Predictive factors for the therapeutic effect of dabigatran on portal vein thrombosis or Budd-Chiari syndrome 3) Comparison of therapeutic effect between warfarin and dabigatran for portal vein thrombosis or Buddd-Chiari syndrome | — |
Countries
Japan
Contacts
Public ContactHitoshi Maruyama
Chiba University Graduate School of Medicine Gastroenterology and Nephrology
Outcome results
None listed